A. Saklad

Neuropsychiatric syndromes in lupus

G. Gronseth, C. Valdez, A. Escalante, 2002 .

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study

R. Vasan, A. Beiser, J. Cavazos, 2022, bioRxiv.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions

G. Gronseth, C. Valdez, A. Escalante, 2002, Neurology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Validating a computerized neuropsychological test battery for mixed ethnic lupus patients

C. Valdez, A. Escalante, R. Brey, 2003, Lupus.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.